Structure Therapeutics Stock Rises 101.6% to $69.67
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Structure Therapeutics is up 101.6%, or $35.11 to $69.67.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STRO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STRO
Wall Street analysts forecast STRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STRO is 17.96 USD with a low forecast of 0.80 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 14.920
Low
0.80
Averages
17.96
High
51.00
Current: 14.920
Low
0.80
Averages
17.96
High
51.00
About STRO
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sutro Biopharma CEO to Present at 44th J.P. Morgan Healthcare Conference
- Conference Appearance: Sutro Biopharma CEO Jane Chung will present at the 44th J.P. Morgan Healthcare Conference on January 15, 2026, at 11:15 AM PT in San Francisco, showcasing the company's innovations in antibody-drug conjugates (ADCs), which is expected to attract investor interest and enhance the company's visibility.
- Live Webcast: The presentation will be accessible via a live webcast on the company's Investor Relations page, with an archived replay available for at least 30 days post-event, ensuring that investors unable to attend can still access key information, thereby enhancing investor engagement and trust.
- Technological Platform: Sutro's next-generation ADC platform aims to deliver single- and dual-payload ADCs by optimizing antibodies, linkers, and payloads, designed to improve drug exposure, reduce side effects, and expand treatable tumor types, demonstrating the company's technological edge in cancer therapy.
- Market Potential: Sutro's ADC pipeline targets large oncology markets with limited treatment options and significant need for improved therapies, indicating the company's strategic positioning to meet unmet medical needs in the oncology sector.
Continue Reading
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
- Clinical Advancement: GT Biopharma has advanced its GTB-3650 clinical trial to Cohort 4, where patients are receiving a dosing of 10μg/kg/day, indicating potential efficacy against resistant blood cancers, with further results expected in Q1 2026.
- Safety Confirmation: Six patients across Cohorts 1, 2, and 3 have successfully completed treatment with GTB-3650, establishing the therapy's safety profile at escalating doses without any dose-limiting toxicities, thereby enhancing confidence in the clinical trial.
- Dose Escalation Plan: The trial is designed to include seven cohorts, with plans to enroll two patients per cohort, escalating doses from 1.25μg/kg/day to potentially 100μg/kg/day, demonstrating the company's ongoing commitment to efficacy and patient care.
- Therapeutic Prospects: GT Biopharma is also advancing GTB-5550, with regulatory submission for human trials expected in late December 2025 or January 2026, further expanding its market opportunities in cancer treatment.
Continue Reading